JANSSEN Company Profile
✉ Email this page to a colleague
What is the competitive landscape for JANSSEN, and when can generic versions of JANSSEN drugs launch?
JANSSEN has seventy-nine approved drugs.
There are seventy-nine US patents protecting JANSSEN drugs.
There are two thousand two hundred and sixty-seven patent family members on JANSSEN drugs in seventy-two countries and four hundred and forty-three supplementary protection certificates in twenty countries.
Summary for JANSSEN
| International Patents: | 2267 |
| US Patents: | 79 |
| Tradenames: | 75 |
| Ingredients: | 51 |
| NDAs: | 79 |
| Patent Litigation for JANSSEN: | See patent lawsuits for JANSSEN |
| PTAB Cases with JANSSEN as patent owner: | See PTAB cases with JANSSEN as patent owner |
Drugs and US Patents for JANSSEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Pharms | PROPULSID | cisapride monohydrate | SUSPENSION;ORAL | 020398-001 | Sep 15, 1995 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Janssen Pharms | ULTRAM | tramadol hydrochloride | TABLET;ORAL | 020281-002 | Mar 3, 1995 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Janssen Pharms | XARELTO | rivaroxaban | TABLET;ORAL | 022406-004 | Oct 11, 2018 | RX | Yes | No | 10,828,310*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Janssen Therap | SIRTURO | bedaquiline fumarate | TABLET;ORAL | 204384-001 | Dec 28, 2012 | RX | Yes | Yes | 7,498,343 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for JANSSEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Janssen Pharms | RISPERDAL | risperidone | TABLET, ORALLY DISINTEGRATING;ORAL | 021444-001 | Apr 2, 2003 | 4,804,663*PED | ⤷ Sign Up |
| Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | 7,470,506 | ⤷ Sign Up |
| Janssen Pharms | TOPAMAX | topiramate | CAPSULE;ORAL | 020844-002 | Oct 26, 1998 | 6,503,884*PED | ⤷ Sign Up |
| Janssen Pharms | RISPERDAL CONSTA | risperidone | INJECTABLE;INTRAMUSCULAR | 021346-001 | Oct 29, 2003 | 6,379,704*PED | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for JANSSEN drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Orally Disintegrating Tablets | 3 mg and 4 mg | ➤ Subscribe | 2005-03-23 |
| ➤ Subscribe | Extended-release Tablets | 18 mg, 27 mg, 36 mg and 54 mg | ➤ Subscribe | 2005-07-19 |
| ➤ Subscribe | Tablets | 250 mg | ➤ Subscribe | 2015-04-28 |
| ➤ Subscribe | Tablets | 6.25 mg and 12.5 mg | ➤ Subscribe | 2005-12-08 |
| ➤ Subscribe | Extended-release Capsules | 8 mg | ➤ Subscribe | 2006-03-02 |
| ➤ Subscribe | Tablets | 100 mg and 300 mg | ➤ Subscribe | 2017-03-29 |
| ➤ Subscribe | Oral Solution | 10 mg/mL | ➤ Subscribe | 2013-05-03 |
| ➤ Subscribe | Tablets | 50 mg | ➤ Subscribe | 2005-09-08 |
| ➤ Subscribe | Transdermal System | 0.15 mg/0.02 mg per 24 hours | ➤ Subscribe | 2007-03-22 |
| ➤ Subscribe | Oral Solution | 25 mg/mL | ➤ Subscribe | 2009-07-30 |
| ➤ Subscribe | Orally Disintegrating Tablets | 0.25 mg | ➤ Subscribe | 2005-04-11 |
| ➤ Subscribe | Extended-release Injectable Suspension | 39 mg/0.25 mL,78 mg/0.5 mL,117 mg/0.75 mL,156 mg/mL and234 mg/1.5 mL | ➤ Subscribe | 2017-11-21 |
| ➤ Subscribe | Extended-release Tablets | 18 mg*, 27 mg, 36 mg and 54 mg | ➤ Subscribe | 2005-07-19 |
| ➤ Subscribe | Tablets | 500 mg | ➤ Subscribe | 2017-08-23 |
| ➤ Subscribe | Tablets | 50 mg/500 mg, 50mg/1000 mg, 150mg/500 mg, and150 mg/1000 mg | ➤ Subscribe | 2017-03-29 |
| ➤ Subscribe | Extended-release Capsules | 16 mg and 24 mg | ➤ Subscribe | 2006-03-11 |
| ➤ Subscribe | Tablets | 800 mg | ➤ Subscribe | 2013-05-14 |
| ➤ Subscribe | Tablets | 25 mg, 100 mg and 200 mg | ➤ Subscribe | 2001-12-26 |
| ➤ Subscribe | Capsules | 15 mg and 25 mg | ➤ Subscribe | 2005-09-07 |
| ➤ Subscribe | Tablets | 10 mg, 15 mg, and 20 mg | ➤ Subscribe | 2015-07-01 |
| ➤ Subscribe | Tablets | 4 mg, 8 mg and 12 mg | ➤ Subscribe | 2005-02-28 |
International Patents for JANSSEN Drugs
Supplementary Protection Certificates for JANSSEN Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2487163 | 122016000120 | Germany | ⤷ Sign Up | PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCHES AKZEPTABLES SALZ DAVON UND ATAZANAVIR ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1025 20150713 |
| 1651658 | 92426 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: CANAGLIFLOZINE |
| 1453521 | 15C0050 | France | ⤷ Sign Up | PRODUCT NAME: ETHINYLESTRADIOL ET MELANGE DE LEVONORGESTREL ET ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: NL 42237 20150320; FIRST REGISTRATION: SK - 17/0017/15-S 20150129 |
| 2049506 | 15C0078 | France | ⤷ Sign Up | PRODUCT NAME: COBICISTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE COBICISTAT; REGISTRATION NO/DATE: EU/1/13/830/001-002 20130527 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
